Background: Sensitization to Staphylococcus aureus enterotoxins (SEs) augments eosinophilic inflammation in asthma. Recent epidemiologic studies demonstrate that sensitization to SEs is increased in healthy smokers; however, there is no evidence on the association between sensitization to SEs and eosinophilic inflammation in smokers with asthma. Objective: To clarify the role of SEs on clinical indexes, including eosinophilic inflammation and lung function in smokers with asthma. Methods: The frequency of atopic sensitization to SEs was examined in adult patients with asthma. In current or ex-smokers with asthma, the association of sensitization to SEs with eosinophilic inflammation, airflow limitation, or treatment steps was determined. Clinical indexes were examined at the first visit, and treatment steps were assessed 6 months after enrollment. Results: Overall, 23 current smokers, 40 ex-smokers, and 118 never smokers with asthma were enrolled. The frequency of sensitization to SEs, but not to other aeroallergens, was significantly higher in current, ex-, and never smokers, in decreasing order. In current or ex-smokers with asthma, patients with sensitization to SEs exhibited higher serum levels of total and specific IgE to aeroallergens, higher blood eosinophil counts, greater airflow limitation, and more severe disease 6 months later than those without sensitization to SE. A longer smoking abstinence period was associated with serum specific IgE levels to SEs, and 3 years was the best cutoff of abstinence period to predict the absence of sensitization to SEs. Conclusion: Sensitization to SEs is increased in smokers with asthma, and it may be a marker of eosinophilic inflammation and severe asthma in smokers with asthma. Trial Registration: umin.ac.jp Identifier: UMIN000007818.
Introduction
Staphylococcus aureus is an opportunistic human pathogen and a commensal on human skin. It is frequently found in the nose. Accumulating evidence on S aureus enterotoxins (SEs) in allergic conditions suggests that the sensitization to SEs modifies the pathophysiologic findings of asthma and chronic rhinosinusitis with nasal polyposis.
1e3 SEs induce human dendritic cells to undergo a type 2 cell polarization by acting as superantigens 4 and promote type 2 or eosinophilic inflammation in both in vitro 4e7 and in vivo studies. 8, 9 Huvenne et al 10 found that the concomitant application of ovalbumin and SE type B (SEB) facilitated sensitization to ovalbumin and eosinophilic airway inflammation. Furthermore, SEs induce the production of their specific IgE antibodies, and sensitization to SEs is associated with asthma severity 11, 12 and type 2 or eosinophilic inflammation, particularly in late-onset asthma or seemingly intrinsic asthma, as revealed in human studies. 13, 14 Epidemiologic studies from Europe and Korea revealed that sensitization to SEs was significantly associated with asthma in the general population. 15, 16 More importantly, current smoking was associated with the frequent sensitization to SEs in epidemiologic studies. 15, 16 It is well known that smoking increases airway inflammation, particularly neutrophilic inflammation, in patients with asthma. 17e19 Moreover, exposure to SEB alone induces neutrophilic inflammation in animal models 20 ; however, when considering the frequent sensitization to SEs in smokers in the general population, it is plausible that sensitization to SEs is increased in smokers with asthma and may augment IgE or eosinophilic inflammation. This finding is supported by previous studies 21, 22 demonstrating that not only neutrophilic but also IgE or eosinophilic inflammation is increased in the airways of smokers with asthma. Therefore, the effects of sensitization to SEs in smokers with asthma remain unknown. In this study, we aimed to clarify the role of sensitization to SEs in smokers with asthma by assessing the frequency of sensitization to SEs in current and ex-smokers with asthma and the effects of sensitization to SEs on inflammation and disease severity.
Methods
Adult patients with asthma who had never smoked or had smoked for more than 5 pack-years were enrolled at their first visit to the asthma clinic at Kyoto University Hospital between October 2013 and October 2015, irrespective of their treatment condition. Asthma was diagnosed according to the American Thoracic Society criteria. 23 Ex-smokers were determined as those who had stopped smoking for at least 3 months. Patients who had abnormal radiographic findings and other pulmonary diseases, except for chronic obstructive pulmonary disease (COPD), as comorbid conditions were excluded. The smoking status and presence of allergic rhinitis, atopic dermatitis, and sinusitis were based on self-reported questionnaires and medical history interview and/or examination performed by specialists. The study protocol was approved by the Ethics Committee of Kyoto University, and oral consent was obtained from all patients.
At their first visit, the patients underwent a workup examination that included questionnaires, a physical examination, blood tests, chest radiography, fractional exhaled nitric oxide measurement, and spirometry. Serum total and specific IgE levels against common aeroallergens, including mixed grass pollens (orchard grass, sweet vernal grass, Bermuda grass, timothy grass, and reeds), mixed molds (Penicillium, Cladosporium, Aspergillus, Candida, Alternaria, and Helminthosporium), weed, house dust mite, Japanese cedar pollen, cat dander, and dog dander, were measured using ImmunoCAP (Phadia, Tokyo, Japan). The patients were considered atopic when serum specific IgE levels to one or more aeroallergens were 0.35 UA/mL or higher. Sensitization to SEs (ImmunoCAP) was determined when specific IgE levels to SEs were 0.10 UA/mL or higher. 12 Fractional exhaled nitric oxide level was measured at a constant exhalation flow rate of 50 mL per second using a chemiluminescence analyzer (NOA 280, Sievers, Boulder, Colorado), 24 according to the current guidelines. 25 Prebronchodilator and postbronchodilator (inhalation of 200 mg of salbutamol), forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and the forced expiratory flow between 25% and 75% (FEF 25%-75% ) were measured using a ChestGraph HI-801 spirometer (Chest MI Corp, Tokyo, Japan), according to the guidelines of the American Thoracic Society. 26 The treatment steps were assessed according to the Global Initiative for Asthma (GINA) 2016 guidelines 6 months after enrollment. The sample size was determined based on the means (SDs) of the serum total IgE levels in patients with and without sensitization to SEs in our previous study. 14 Overall, 60 current or ex-smokers with asthma were estimated to be necessary to detect the differences in serum total IgE levels between patients with and without sensitization to receiver operating characteristic (ROC) analysis was performed to determine the cutoff of the smoking abstinence period to predict the absence of sensitization to SEs. The data were expressed as means (SDs). P < .05 was considered significant.
Results
Overall, 181 patients with asthma were enrolled (Fig 1) , 63 of whom were current or ex-smokers. Twenty-six patients had been enrolled in our previous study. The clinical characteristics of current smokers, ex-smokers, and never smokers with asthma are presented in Table 1 . A higher proportion of current or exsmokers were men and had higher blood eosinophil counts and lower FEV 1 /FVC and FEF 25%-75% than never smokers. The frequency of sensitization to SE type A (SEA) and/or SEB was significantly higher in the current smokers (65%), ex-smokers (35%), and never smokers (31 %), in decreasing order (P ¼ .006) (Fig 1 and Fig 2) . Particularly, current smoking was a risk factor for sensitization to SEA and/or SEB, with an odds ratio of 3.99 (95% CI, 1.52e11.2; P ¼ .005) compared with never smoking and 3.05 (95% CI, 1.03e9.57; P ¼ .04) compared with exsmoking, after adjusting for sex, age at enrollment, and GINA treatment step 4 and 5 at 6 months after enrollment. Meanwhile, the frequencies of sensitization to other aeroallergens did not significantly differ among the 3 patient groups. The frequencies of comorbidities (atopic dermatitis, allergic rhinitis, and sinusitis) were not different among the 3 patient groups or between patients with and without sensitization to SEs. Subsequently, our analysis was confined to current or exsmokers. Sensitization to SEA and SEB was associated with higher serum total IgE levels and greater frequency of sensitization to other aeroallergens, including molds, house dust mite, dog dander, and weed ( Table 2 and Table 3 ). These findings were also observed when current or ex-smokers with asthma were stratified according to the sensitization status to both SEA and SEB or either SEA or SEB (eTable 1 and eTable 2). Current or ex-smokers with sensitization to SEB exhibited higher blood eosinophil counts and greater airway reversibility than those without sensitization to SEB (Table 2) . Lower FEV 1 and FEV 1 /FVC at enrollment and higher frequencies of GINA treatment step 5 at 6 months after enrollment were significantly associated with sensitization to SEA (Table 3 ) and marginally with sensitization to SEB ( Table 2 ). The specific IgE levels to SEA (r ¼ 0.33, P ¼ .008) and SEB (r ¼ 0.28, P ¼ .03) were weakly but significantly associated with GINA treatment steps 6 months after enrollment (Fig 2 and Fig 3) . Characteristics of never smokers with asthma stratified according to the sensitization status to SEB and SEA (eTable 3) are also presented in the online supplement.
Finally, in the analysis of current or ex-smokers, a longer duration after smoking cessation was significantly associated with lower specific IgE levels to SEA and marginally for specific IgE levels to SEB (Table 4) . None of the other aeroallergen specific IgE levels were associated with the smoking abstinence period. An ROC curve analysis revealed that 3 years after smoking cessation was the best cutoff for predicting the absence of sensitization to SEA or SEB in current or ex-smokers with asthma, with a sensitivity of 0.71 and specificity of 0.66 (Fig 3 and Fig 4) . The area under the ROC curve was 0.675. 
Discussion
To the best of our knowledge, this is the first study to find that among patients with asthma, sensitization to SEs, but not other aeroallergens, was more common in current or ex-smokers than in never smokers. In addition, sensitization to SE augmented IgE or eosinophilic inflammation, airflow limitation, and treatment intensity in current or ex-smokers with asthma. Notably, sensitization to SEs decreased in association with a longer smoking abstinence period.
The overall frequency of sensitization to SEs in the present study was 48%, which was similar to that in patients with asthma in the GA2LEN study (41%) 15 and the results presented by Bachert et al (41%). 12 In this study, the frequency of sensitization to SEs in current or ex-smokers was significantly higher than that in never smokers with asthma; its frequency in current smokers with asthma increased to 65%, whereas the frequency of sensitization to other aeroallergens did not differ between current or ex-smokers and never smokers with asthma. These findings are consistent with findings of the general population in the GA2LEN study, which demonstrated that compared with never smokers, current smokers were more frequently sensitized to SEs, with an odds ratio of 2.02, but not to house dust mite or other tested aeroallergens. 15 Although the mechanisms underlying the increased frequency of sensitization to SEs in current or ex-smokers with asthma remain unclear, 2 potential mechanisms should be discussed: (1) increased type 2 proinflammatory responses of epithelial cells to microorganisms in smokers with asthma, which may be represented by increased thymic stromal lymphopoietin levels in the airways, 22, 27, 28 and (2) increased colonization of S aureus in the airways. Cigarette smoke disrupts the bronchial epithelial barrier, leading to increased S aureus colonization on epithelial cells, which may serve as a reservoir of SEs by the formation of biofilms, 29 induces SEs penetration into subepithelial layers, and increases stimulation of T cells. 30 However, the influence of current smoking on S aureus nasal colonization in healthy individuals yielded conflicting results. Bogaert et al 31 found that active and passive smoking were risk factors for nasal colonization in children aged 1 to 19 years, whereas Andersen et al 32 found that current smoking reduced risk of S aureus nasal colonization in middle-aged and elderly twins. Therefore, the effects of smoking on S aureus colonization and responses to S aureus in the lower airways of patients with asthma should be clarified in future studies. As expected, current or ex-smokers with sensitization to SEs were more frequently sensitized to other aeroallergens, and they had higher serum total IgE levels and eosinophil counts than those without sensitization to SEs. These data agree with the findings of various clinical studies 11e14,33 and mice models 9,10 of allergic Figure 3 . Association between specific IgE levels to a Staphylococcus aureus enterotoxin A (SEA) (A) or S aureus enterotoxin B (SEB) (B) and the Global Initiative for Asthma (GINA) treatment steps 6 months after study enrollment in current or ex-smokers with asthma. asthma, and they may be explained by its nature of superantigens. 3, 10 Notably, current or ex-smokers with asthma who were sensitized to weed were all sensitized to SEs as well, but the mechanism underlying this sensitization remains unknown. Sensitization to SE was clinically associated with airflow limitation and GINA treatment step 5 at steady-state conditions in current or ex-smokers with asthma in the present study. Therefore, sensitization to SE may play an important role in smokers with asthma and could be a potential marker of type 2 or eosinophilic inflammation and severe disease in this population. Although the effect of sensitization to SEA and SEB on clinical indexes exhibited similar trends in current or ex-smokers with asthma, higher blood eosinophil counts and greater airway reversibility were associated with sensitization to SEB. In contrast, airflow limitation, severe asthma, and a shorter smoking abstinence period were associated with sensitization to SEA alone. Although the specific mechanisms behind these associations remain unknown, similar results were observed in previous studies. SEB augmented type 2 or eosinophilic inflammation in animal models 9, 10 and sensitization to SEA alone was associated with poor asthma control 14, 33 in patients with asthma, not restricted to smokers with asthma. Vulnerable conditions with impaired barrier integrity may be necessary to establish sensitization to SEA, when considering that the rate of transcytosis of SEA was several-fold slower than that of SEB in a study using intestinal epithelial cells. 34 Therefore, sensitization to SEA, rather than SEB, would be a potential marker of severe disease in current or exsmokers with asthma. One of our important findings was that patients with a longer duration after smoking cessation had lower levels of SE specific IgE, particularly, SEA specific IgE. Furthermore, we observed that 3 years of smoking abstinence was the cutoff for predicting the absence of sensitization to SEs. These associations were not observed for other aeroallergens. It is possible to speculate that impaired airway barrier integrity and an overproduction of mucin that binds SA 35 may be normalized after smoking cessation, which reduces the burden of SEs. A small study recently found that smoking abstinence for 3 months did not alter the microbial diversity in the lower airways of patients with asthma. 36 Therefore, it may take several years to detect a change in the lung microbial communities and to be desensitized to SEs after smoking cessation. In fact, it took 2 years after smoking cessation to normalize CD4 þ cell counts 37 and goblet cell hyperplasia. 38 Our study has several limitations. First, we did not provide microbiological data, including S aureus colonization in the lower airways. Second, smoking status and duration after smoking cessation were based on a self-reported questionnaire. Therefore, S aureus colonization and objective measures of smoking status, such as cotinine levels, should be evaluated in future studies. Prospective longitudinal studies that follow SE sensitization levels after smoking cessation are warranted. Third, we included current or exsmokers with COPD as a comorbid condition of asthma. However, the inclusion of patients with asthma-COPD overlap may not critically detract from our conclusion because patients with COPD were sensitized to SEs with a frequency of 56%, 39 indicating the presence of a similar association between smoking and sensitization to SEs in patients with COPD. Further studies are necessary to investigate the role and specific mechanisms of sensitization to SEs in patients with asthma-COPD overlap.
In conclusion, smoking may facilitate sensitization to SEs in patients with asthma. Sensitization to SEs may be a key marker in smokers with asthma, indicating the presence of IgE or eosinophilic inflammation, airflow limitation, and severe disease.
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